



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Robert M David, Ph.D

PATIENT

DEMOGRAPHICS

Patient Name: Velma Gilchriest	Account: Premier Mountain Healthcare	Order Code: NE22-0007294
DOB: 01/24/1944	Provider: Leon Driss	Sample Type: Urine
Patient Gender: F	Accession: 22040800055	Collected: 04/05/2022
Patient Phone Number:	Report Status: FINAL	Received: 2022-04-08T13:48:53.721294
		Reported: 04/13/2022

PRESCRIPTION

LIST

Losartan (Cozaar) , Atenolol (Tenormin) , Nadolol (Corgard) , Amlodipine (Norvasc) , Atorvastatin (Lipitor) , Levothyroxine (Synthroid , Tirosint , Levoxyl) , Albuterol (ProAir HFA , Ventolin HFA , ProAir RespiClick , Proventil HFA , Proventil , AccuNeb , Ventolin Injection , Ventolin Nebules PF , Ventolin Oral Liquid , Ventolin Respirator Solution , Vospire ER) , Fluticasone (Aller-Flo , Flovent Diskus , Ticanase , Flovent HFA , ClariSpray , ArmonAir RespiClick , Cutivate , Ticaspray , Flonase Allergy Relief) , Aspirin (Arthritis Pain , Aspi-Cor , Aspir 81 , Aspir-Low , Bayer Plus , Bufferin , Durlaza , Ecotrin , Ecpirin , Miniprin , Vazalore)

DIAGNOSIS

CODES

Z51.81, Z79.899, E11.9 Type 2 diabetes mellitus without complications, E78.4 Other hyperlipidemia

INCONSISTENT				INCONSISTENT			
NOT PRESCRIBED		DETECTED		PRESCRIBED		NOT DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)	Class	Test	Cutoff (ng/mL)	
ANTIDIABETIC	Metformin	500	> 25000	BETA BLOCKER	Atenolol	50	
[DDI] The therapeutic efficacy of Metformin can be increased when used in combination with Nadolol. [DDI] Salicylic acid may increase the hypoglycemic activities of Metformin. [DDI] Metformin may increase the hypolipidaemic activities of Atorvastatin. [DDI] The therapeutic efficacy of Metformin can be decreased when used in combination with Levothyroxine. [DDI] Metformin may decrease the excretion rate of Salbutamol which could result in a higher serum level. [DDI] The therapeutic efficacy of Metformin can be decreased when used in combination with Fluticasone. [DDI] The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Metformin.				[DDI] Atenolol may decrease the excretion rate of Atorvastatin which could result in a higher serum level. [DDI] Atenolol may increase the arrhythmogenic activities of Nadolol. [DDI] Salicylic acid may decrease the antihypertensive activities of Atenolol. [DDI] The therapeutic efficacy of Salbutamol can be decreased when used in combination with Atenolol. [DDI] Atenolol may increase the arrhythmogenic activities of Losartan. [DDI] The risk or severity of adverse effects can be increased when Atenolol is combined with Caffeine. [DDI] The serum concentration of Metformin can be increased when it is combined with Atenolol. [DDI] Atenolol may increase the arrhythmogenic activities of Amlodipine. [DDI] The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Atenolol. [DDI] Acetylsalicylic acid may decrease the antihypertensive activities of Atenolol.			
STIMULANT	Caffeine	50	330.34				
[DDI] Levothyroxine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.							

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
Losartan	[DDI] Losartan may increase the arrhythmogenic activities of Nadolol.	
Levothyroxine	[DDI] The therapeutic efficacy of Levothyroxine can be increased when used in combination with Acetylsalicylic acid. [DDI] The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Nadolol. [DDI] The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluticasone.	
Albuterol	[DDI] Nadolol may decrease the bronchodilatory activities of Salbutamol. [DDI] The risk or severity of QTc prolongation can be increased when Losartan is combined with Salbutamol.	
Fluticasone	[DDI] The risk or severity of hypokalemia can be increased when Fluticasone is combined with Salbutamol. [DDI] The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluticasone.	

CONSISTENT				VALIDITY TESTING & SCREENS		
PRESCRIBED		DETECTED		Specimen Validity	Range	Results
Class	Test	Cutoff (ng/mL)	Results (ng/mL)	PH	4.50 - 8.00	6.6
CARDIOVASCULAR	Amlodipine	25	510.14	Specific Gravity	1.01 - 1.03	1.012
[DDI] The metabolism of Amlodipine can be increased when combined with Fluticasone. [DDI] The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Metformin. [DDI] Salicylic acid may decrease the antihypertensive activities of Amlodipine. [DDI] Amlodipine may increase the arrhythmogenic activities of Nadolol. [DDI] Salbutamol may decrease the antihypertensive activities of Amlodipine. [DDI] Acetylsalicylic acid may decrease the antihypertensive activities of Amlodipine.				Urine Creatinine (mg/dL)	20.00 - 400.00	118.78
STATIN	Atorvastatin	10	29.17			
[DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Atorvastatin can be decreased when combined with Levothyroxine. [DDI] The metabolism of Atorvastatin can be decreased when combined with Fluticasone.						
NSAID	Salicylic Acid	400	> 20000			
Metabolite of Acetylsalicylic Acid [DDI] The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Acetylsalicylic acid. [DDI] The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Salbutamol. [DDI] The risk or severity of adverse effects can be increased when Fluticasone is combined with Acetylsalicylic acid. [DDI] Acetylsalicylic acid may decrease the antihypertensive activities of Nadolol. [DDI] The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Salicylic acid. [DDI] Salicylic acid may decrease the antihypertensive activities of Nadolol. [DDI] The therapeutic efficacy of Levothyroxine can be increased when used in combination with Salicylic acid. [DDI] The risk or severity of hypertension can be increased when Salicylic acid is combined with Salbutamol. [DDI] The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Salicylic acid. [DDI] The risk or severity of adverse effects can be increased when Salicylic acid is combined with Acetylsalicylic acid.						



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Robert M David, Ph.D

PATIENT

DEMOGRAPHICS

Patient Name: Velma Gilchriest	Account: Premier Mountain Healthcare	Order Code: NE22-0007294
DOB: 01/24/1944	Provider: Leon Driss	Sample Type: Urine
Patient Gender: F	Accession: 22040800055	Collected: 04/05/2022
Patient Phone Number:	Report Status: FINAL	Received: 2022-04-08T13:48:53.721294
		Reported: 04/13/2022

NOT PRESCRIBED						NOT DETECTED			
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
Carboxyibuprofen	400	Buspirone	50	Gabapentin	1000	N-Desmethyloanzapine	25	Rivaroxaban	50
Digoxin	10	Butalbital	100	Glipizide	10	N-Desmethyltapentadol	50	Temazepam	40
Ethyl Glucuronide	500	Carbamazepine	50	Glyburide	10	Norbuprenorphine	30	THC-COOH	50
Ethyl Sulfate	200	Carbamazepine Epoxide	50	Haloperidol	25	Nordiazepam	40	Topiramate	50
Lisinopril	50	Carboxyclopidogrel	50	Hydrochlorothiazide	50	Norfentanyl	8	Tramadol	100
Norverapamil	50	Carboxyzolpidem	50	Hydrocodone	50	Norhydrocodone	50	Trazodone	50
Rosuvastatin	20	Carisoprodol	100	Hydromorphone	50	Norketamine	10	Valsartan	50
Sertraline	50	Celecoxib	50	Hydroxybupropion	50	Normeperidine	100	Venlafaxine	100
Sitagliptin	50	Chlorpromazine	25	Imipramine	50	Noroxycodone	50	Warfarin	10
Sufentanil	5	Clonazepam	20	Indomethacin	50	Norpropoxyphene	100	Zaleplon	10
Sumatriptan	50	Clonidine	50	Irbesartan	50	Nortriptyline	50	Ziprasidone	25
Tapentadol	50	Codeine	50	Levetiracetam	50	O-Desmethyltramadol	100	Zolmitriptan	50
4-Hydroxydiclofenac	50	Cotinine	50	Lorazepam	40	O-Desmethylvenlafaxine	100		
6-MAM	25	Cyclobenzaprine	50	Lurasidone	25	Olanzapine	25		
7-Aminoclonazepam	40	Dehydroaripiprazole	20	MDA	100	Oxazepam	40		
7-Aminoflunitrazepam	40	Desalkylflurazepam	40	MDMA	100	Oxycodone	50		
9-Hydroxyrisperidone	10	Desipramine	50	Meprobamate	200	Oxymorphone	50		
Acetaminophen	400	Dextrorphan	25	Methadone	100	Paroxetine	25		
a-Hydroxymidazolam	30	Diazepam	10	Methamphetamine	100	Phencyclidine	10		
a-Hydroxytriazolam	30	Diclofenac	50	Methotrexate	50	Phenobarbital	100		
alpha-Hydroxyalprazolam	30	Dihydrocodeine	50	Metoprolol	50	Phentermine	100		
Alprazolam	30	Diltiazem	50	Mitragynine	25	Pioglitazone	50		
Amitriptyline	50	Diphenhydramine	50	Morphine	50	Pitavastatin	10		
Amphetamine	200	Donepezil	50	Mycophenolic acid	50	Pregabalin	150		
Apixaban	25	Doxepin	30	Naloxone	10	Propranolol	50		
Aripiprazole	20	Duloxetine	50	Naltrexone	10	Protriptyline	50		
Atomoxetine	50	EDDP	100	Naproxen	100	Pseudoephedrine	50		
Baclofen	50	Fentanyl	2	N-Desmethycitalopram	50	Quetiapine	50		
Benzoylcegonine	50	Fluoxetine	25	N-Desmethylozapine	25	Risperidone	10		
Buprenorphine	10	Furosemide	50	N-Desmethylmirtazapine	25	Ritalinic Acid	50		

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.